PF_ILD_INBUILD_trial_meets_primary_endpoint

INBUILD ® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases1New data showed positive effect of nintedanib on slowing decline of lung function in a broad range of fibrosing interstitial lung diseases with a progressive phenotype1Phase III results published in the New England Journal of Medicine and to be presented at the European Respiratory Society (ERS) International Congress in Madrid, SpainRegulatory applications were recently submitted for this new indication with the FDA and EMA
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news